2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 598

Anti-Drug Antibodies As a Predictor for the Discontinuation of Anti-TNF Agents in Patients with Spondyloarthrtis
Abstract Number: 3002

Anti-Fibrotic Effects of a Newly Discovered HGF Receptor Carboxy-Terminal Fragment in Systemic Sclerosis
Abstract Number: 769

Anti-Fibrotic Effects of an Investigational Drug: Bis-Oxetanyl Sulfoxide
Abstract Number: 2345

Anti-IL-6 Receptor Antibody Prevents Deterioration in Bone Structure in a Mouse Model of Collagen-Induced Arthritis
Abstract Number: 323

Anti-Inflammatory Marine Compound, Lyy-B2, Ameliorates Rheumatoid Arthritis through Inhibition of Osteoclast Differentiation
Abstract Number: 2457

Anti-Major Histocompatibility Complex Class I-Related Chain a (MICA) Antibodies in Rheumatoid Arthritis Patients with Interstitial Lung Disease
Abstract Number: 1037

Anti-MDA5 Antibody Associated Myositis Compared to DM Patient: A Distinct Muscular Pattern Associated with a shared IFN Signature
Abstract Number: 1266

Anti-MDA5 Is Associated with Rapidly-Progressive Interstitial Lung Disease and Poor Survival in U.S. Patients with Amyopathic and Myopathic Dermatomyositis
Abstract Number: 1835

Anti-Osteoporosis Medication Use after Hip or Vertebral Fracture
Abstract Number: 1317

Anti-p155/140 Autoantibodies and Selected Features at Illness Onset Are Associated with a Chronic Course of Illness in the Juvenile Idiopathic Inflammatory Myopathies
Abstract Number: 1474

Anti-Peptidyl Arginine Deiminase 4 Antibodies in African-Americans with Rheumatoid Arthritis and Radiographic Scores
Abstract Number: 398

Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding in Rheumatoid Arthritis (RA)
Abstract Number: 2991

Anti-Ribosomal P Antibody Is a Key Autoantibody Associated with Complications of NP-SLE with High-Levels of CSF IL-8
Abstract Number: 1827

Anti-Ro and Anti-La Antibodies in the General Pregnant Population
Abstract Number: 2543

Anti-Ro/SSA Positive Incomplete Sjögren’s Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].